Peter Attia and Longevity / TRT: The Documented Public Record

By
Published Updated Last reviewed
Hormone therapy clinical care image for Peter Attia and Longevity / TRT: The Documented Public Record

At a glance

  • Celebrity: Peter Attia, MD
  • Drug family: Longevity / TRT
  • Status: Confirmed personal use of testosterone replacement therapy and rapamycin (sirolimus)
  • Primary public sources: Outlive (2023), The Peter Attia Drive podcast (2018-present), multiple long-form interviews
  • Clinical relevance: TRT for age-related testosterone decline; rapamycin as an mTOR inhibitor studied for geroprotective effects

Who Is Peter Attia?

Peter Attia is a Canadian-American physician who left a surgical oncology fellowship at Johns Hopkins to focus on applied longevity science. He founded Early Medical, a practice centered on what he calls "Medicine 3.0," a proactive framework that prioritizes lifespan and healthspan over reactive disease treatment. His 2023 bestseller Outlive sold over two million copies and became the most commercially successful longevity medicine book in a decade.

What sets Attia apart from other public health figures is his willingness to disclose his own pharmacological interventions. On his podcast The Drive, he has discussed blood work, body composition data, and specific drug protocols with a transparency unusual for a practicing physician. This openness has made him a central figure in public conversations about testosterone optimization and off-label rapamycin use.

The Confirmed Public Record

Testosterone Replacement Therapy

Attia has confirmed TRT use across multiple episodes of The Drive and in interviews with Tim Ferriss and others. He has described his rationale in clinical terms: maintaining testosterone in an optimized physiological range as part of a broader strategy addressing body composition, bone mineral density, and cognitive function.

He has been specific about his reasoning. In a 2021 episode of The Drive, Attia explained that his decision was informed by serial lab monitoring showing a downward trajectory in free testosterone levels, combined with symptomatic changes in recovery and body composition that he attributed to declining androgen status. He has clarified repeatedly that TRT is not something he recommends universally but considers appropriate when lab data, symptoms, and risk assessment align.

Attia has also publicly discussed his monitoring protocol, which includes regular assessment of hematocrit, PSA, estradiol, and lipid panels, a practice consistent with Endocrine Society clinical guidelines for testosterone therapy in men.

Rapamycin (Sirolimus)

Attia's rapamycin use is equally well-documented. He has confirmed taking rapamycin weekly at a low dose in an off-label longevity context. On The Drive, he has discussed the drug's mechanism as an mTOR (mechanistic target of rapamycin) inhibitor and cited the landmark ITP studies showing lifespan extension in mice as foundational to his interest.

In his conversation with researcher Matt Kaeberlein (episode #192 of The Drive), Attia described his dosing approach: a once-weekly protocol designed to achieve intermittent mTOR inhibition rather than the continuous immunosuppression seen in transplant medicine. He has stated that this pulsatile dosing strategy is intended to capture the geroprotective benefits while minimizing immune suppression, a distinction he considers critical.

He has also acknowledged uncertainty. In Outlive, Attia writes that rapamycin is the intervention he finds most intellectually compelling but notes that human longevity data remains absent. He positions his personal use as an informed bet, not a clinical recommendation.

Clinical Context: TRT in the Longevity Setting

Testosterone levels in men decline approximately 1-2% per year after age 30, a process sometimes termed "andropause," though this framing remains debated in endocrinology. The clinical threshold for hypogonadism is generally defined as total testosterone below 300 ng/dL with associated symptoms, according to AUA and Endocrine Society guidelines.

TRT's established effects include improvements in lean body mass, bone mineral density, sexual function, and mood. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, provided the largest cardiovascular safety dataset to date: 5,246 men followed for a mean of 33 months showed no increased incidence of major adverse cardiovascular events with transdermal testosterone versus placebo. This trial substantially changed the risk conversation around TRT, though it studied only men aged 45-80 with pre-existing or high risk of cardiovascular disease.

Common side effects include erythrocytosis (elevated hematocrit), acne, and suppression of endogenous gonadotropins leading to reduced fertility. The FDA label carries a warning about potential cardiovascular risk and venous thromboembolism, though the TRAVERSE data has prompted calls for label revision.

The HealthRX Medical Team take: Attia's approach to TRT, data-driven initiation based on serial labs and symptom correlation, paired with structured monitoring of hematocrit, PSA, and estradiol, represents the standard of care as outlined by the Endocrine Society. His public emphasis on TRT as one variable in a multi-factorial longevity strategy (alongside exercise, sleep, and nutrition) is clinically sound. The risk is that his audience may extract the TRT component from the broader framework. Testosterone therapy requires ongoing medical supervision and is not a standalone longevity intervention.

Clinical Context: Rapamycin and mTOR Inhibition

Rapamycin was originally approved as an immunosuppressant for kidney transplant recipients. Its mechanism, inhibition of the mTOR complex 1 (mTORC1) signaling pathway, regulates cell growth, autophagy, and metabolic sensing. The longevity hypothesis rests on a simple observation: caloric restriction extends lifespan in nearly every model organism tested, and mTOR inhibition partially mimics the downstream signaling of caloric restriction.

The mouse data is striking. The NIA Interventions Testing Program found that rapamycin extended median lifespan by 9-14% even when started late in life, a result replicated across three independent sites. No other pharmacological intervention has shown this degree of reproducibility in mammalian longevity studies.

Human data is far more limited. A 2014 study by Mannick et al. published in Science Translational Medicine demonstrated that low-dose mTOR inhibition (using the rapalog everolimus) improved immune function in elderly subjects, specifically enhancing response to influenza vaccination by approximately 20%. This study is frequently cited as evidence that intermittent, low-dose mTOR inhibition may have different immunological effects than the continuous high-dose protocols used in transplant medicine.

Side effect concerns at transplant-level doses include mouth ulcers, impaired wound healing, hyperlipidemia, hyperglycemia, and immunosuppression. Whether these risks manifest at the low, intermittent doses used in the longevity community remains an open question. A 2023 review in The Lancet Healthy Longevity noted that formal dose-finding studies for geroprotective rapamycin use in humans have not been completed.

The HealthRX Medical Team take: Attia's candor about the evidence gap here is notable and appropriate. The mouse data on rapamycin is the strongest pharmacological longevity signal in preclinical research, but "strongest preclinical signal" is not "proven in humans." His weekly pulsatile dosing strategy is grounded in a plausible pharmacological rationale (intermittent mTORC1 inhibition with recovery windows to preserve immune function), but this protocol has not been validated in randomized controlled trials. Patients considering rapamycin should understand they are participating in an n-of-1 experiment. Lab monitoring for lipids, glucose, and CBC is essential, and any physician prescribing it off-label should be tracking these parameters at minimum quarterly.

The Broader Attia Longevity Framework

Attia's public commentary consistently places pharmacology as one pillar of a four-part framework. The others, which he discusses at greater length in Outlive, are exercise (with specific emphasis on VO2 max training and zone 2 cardio), nutritional biochemistry (he has publicly documented personal experiments with ketosis, time-restricted eating, and continuous glucose monitoring), and sleep optimization.

This framing matters clinically. Attia has repeatedly stated on The Drive that no drug intervention compensates for poor exercise habits or metabolic dysfunction, a position consistent with data showing that cardiorespiratory fitness is among the strongest predictors of all-cause mortality.

He has also publicly discussed and subsequently discontinued certain interventions. He stopped a prolonged fasting protocol he had previously advocated, citing concerns about lean mass loss that outweighed the autophagy benefits. This willingness to revise positions based on evolving personal data adds credibility to his public record, though it also means any snapshot of "Attia's protocol" may not reflect his current practice.

What Remains Speculated or Undisclosed

Attia has mentioned using other compounds and supplements in passing across hundreds of podcast hours, including metformin (which he later stated he discontinued due to concerns about blunting exercise adaptations, citing the MASTERS trial data), various peptides, and NAD+ precursors. The specifics of his current full pharmacological stack beyond TRT and rapamycin are not comprehensively documented in a single public source. Listeners should treat partial mentions on individual podcast episodes as potentially outdated.

His exact TRT dosing, formulation (injectable vs. transdermal vs. pellet), and rapamycin brand or compounding source have not been consistently specified across public appearances.

Frequently asked questions

›
›
›
›
›

References